DD244292A5 - Trockensubstanzen und stabile suspensionen - Google Patents
Trockensubstanzen und stabile suspensionen Download PDFInfo
- Publication number
- DD244292A5 DD244292A5 DD85282435A DD28243585A DD244292A5 DD 244292 A5 DD244292 A5 DD 244292A5 DD 85282435 A DD85282435 A DD 85282435A DD 28243585 A DD28243585 A DD 28243585A DD 244292 A5 DD244292 A5 DD 244292A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- polyethylene glycol
- preparation
- androstene
- hydroxy
- dry substances
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Drying Of Solid Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Magnetic Record Carriers (AREA)
- Plural Heterocyclic Compounds (AREA)
- Glass Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH530584 | 1984-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD244292A5 true DD244292A5 (de) | 1987-04-01 |
Family
ID=4291364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD85282435A DD244292A5 (de) | 1984-11-06 | 1985-11-04 | Trockensubstanzen und stabile suspensionen |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5002940A (da) |
| EP (2) | EP0346953B1 (da) |
| JP (2) | JPS61204118A (da) |
| KR (1) | KR890000907B1 (da) |
| AT (2) | ATE84718T1 (da) |
| AU (2) | AU586988B2 (da) |
| CA (1) | CA1249223A (da) |
| CY (2) | CY1898A (da) |
| DD (1) | DD244292A5 (da) |
| DE (2) | DE3587020D1 (da) |
| DK (1) | DK162510C (da) |
| ES (1) | ES8701491A1 (da) |
| FI (1) | FI85809C (da) |
| GR (1) | GR852637B (da) |
| HK (2) | HK101192A (da) |
| HU (1) | HU195728B (da) |
| IE (2) | IE63156B1 (da) |
| IL (1) | IL76943A (da) |
| MX (1) | MX9203371A (da) |
| NL (1) | NL940015I2 (da) |
| NO (1) | NO169324C (da) |
| NZ (2) | NZ229276A (da) |
| PH (1) | PH21673A (da) |
| PT (1) | PT81429B (da) |
| SG (1) | SG107192G (da) |
| ZA (1) | ZA858481B (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH673395A5 (da) * | 1987-01-30 | 1990-03-15 | Ciba Geigy Ag | |
| MX9201782A (es) * | 1991-04-19 | 1992-10-01 | Sandoz Ag | Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene. |
| CH683151A5 (de) * | 1991-04-24 | 1994-01-31 | Ciba Geigy Ag | Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus. |
| GB2344520A (en) * | 1998-12-08 | 2000-06-14 | Phares Pharm Res Nv | Pharmaceutical carriers comprising lipids and polymers |
| JP2002532389A (ja) * | 1998-12-08 | 2002-10-02 | ファレス ファーマシューティカル リサーチ エヌブイ | リン脂質組成物 |
| US6447806B1 (en) | 1999-02-25 | 2002-09-10 | Novartis Ag | Pharmaceutical compositions comprised of stabilized peptide particles |
| US6487907B1 (en) * | 1999-07-08 | 2002-12-03 | California Institute Of Technology | Microgyroscope with integrated vibratory element |
| US20050100608A1 (en) * | 2003-02-21 | 2005-05-12 | Watson Pharmaceuticals, Inc. | Testosterone oral dosage formulations and associated methods |
| ITMI20032054A1 (it) * | 2003-10-22 | 2005-04-23 | Monteres S R L | Processo per la preparazione di sospensioni farmaceutiche da inalare. |
| WO2009026473A2 (en) * | 2007-08-21 | 2009-02-26 | Hollis-Eden Pharmaceuticals, Inc. | Stabilized therapeutic compositions and formulations |
| WO2019213286A1 (en) * | 2018-05-02 | 2019-11-07 | LifeMax Laboratories, Inc. | Extended release suspension formulation of lurasidone |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2068447A1 (en) * | 1969-11-26 | 1971-08-27 | Orsymonde | Dehydrated pharmaceutical comps by - lyophilisation |
| LU77457A1 (da) * | 1977-05-31 | 1979-01-19 | ||
| US4235893A (en) * | 1978-05-08 | 1980-11-25 | Brodie Angela M | Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis |
| US4391755A (en) * | 1982-01-18 | 1983-07-05 | E. R. Squibb & Sons, Inc. | Steroid monohydrates, formulations containing same and method |
| JPS58206513A (ja) * | 1982-05-28 | 1983-12-01 | Eisai Co Ltd | セクレチン吸着防止組成物および方法 |
| DE3225706C2 (de) * | 1982-07-09 | 1984-04-26 | A. Nattermann & Cie GmbH, 5000 Köln | Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen |
| DE3339295A1 (de) * | 1982-11-15 | 1984-05-17 | Schering AG, 1000 Berlin und 4709 Bergkamen | 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung |
| EP0117811A3 (fr) * | 1983-02-23 | 1987-06-03 | Sanofi S.A. | Compositions pharmaceutiques antifongiques utilisables par voie orale |
| EP0226021A1 (de) * | 1985-12-12 | 1987-06-24 | BBC Brown Boveri AG | Thyristor mit schaltbarem Emitter-Kurzschluss |
-
1985
- 1985-10-28 US US06/792,077 patent/US5002940A/en not_active Expired - Lifetime
- 1985-10-30 JP JP60241761A patent/JPS61204118A/ja active Granted
- 1985-10-31 EP EP89116154A patent/EP0346953B1/de not_active Expired - Lifetime
- 1985-10-31 EP EP85810500A patent/EP0181287B1/de not_active Expired - Lifetime
- 1985-10-31 DE DE8989116154T patent/DE3587020D1/de not_active Expired - Lifetime
- 1985-10-31 AT AT89116154T patent/ATE84718T1/de active
- 1985-10-31 CY CY189885A patent/CY1898A/xx unknown
- 1985-10-31 AT AT85810500T patent/ATE51152T1/de active
- 1985-10-31 DE DE8585810500T patent/DE3576650D1/de not_active Expired - Lifetime
- 1985-11-01 GR GR852637A patent/GR852637B/el unknown
- 1985-11-04 PT PT81429A patent/PT81429B/pt unknown
- 1985-11-04 FI FI854330A patent/FI85809C/fi not_active IP Right Cessation
- 1985-11-04 DD DD85282435A patent/DD244292A5/de not_active IP Right Cessation
- 1985-11-04 CA CA000494486A patent/CA1249223A/en not_active Expired
- 1985-11-04 ES ES548492A patent/ES8701491A1/es not_active Expired
- 1985-11-04 IL IL76943A patent/IL76943A/xx not_active IP Right Cessation
- 1985-11-04 AU AU49344/85A patent/AU586988B2/en not_active Expired
- 1985-11-05 NZ NZ229276A patent/NZ229276A/xx unknown
- 1985-11-05 PH PH33012A patent/PH21673A/en unknown
- 1985-11-05 IE IE275585A patent/IE63156B1/en not_active IP Right Cessation
- 1985-11-05 NO NO854403A patent/NO169324C/no not_active IP Right Cessation
- 1985-11-05 IE IE249090A patent/IE63166B1/en not_active IP Right Cessation
- 1985-11-05 KR KR1019850008247A patent/KR890000907B1/ko not_active IP Right Cessation
- 1985-11-05 NZ NZ214069A patent/NZ214069A/xx unknown
- 1985-11-05 HU HU854256A patent/HU195728B/hu unknown
- 1985-11-05 ZA ZA858481A patent/ZA858481B/xx unknown
- 1985-11-05 DK DK509485A patent/DK162510C/da not_active IP Right Cessation
-
1989
- 1989-09-18 AU AU41504/89A patent/AU633844B2/en not_active Expired
-
1992
- 1992-06-25 MX MX9203371A patent/MX9203371A/es unknown
- 1992-10-14 SG SG1071/92A patent/SG107192G/en unknown
- 1992-12-17 HK HK1011/92A patent/HK101192A/xx not_active IP Right Cessation
-
1993
- 1993-02-10 JP JP5022485A patent/JPH0768130B2/ja not_active Expired - Lifetime
- 1993-10-10 CY CY1677A patent/CY1677A/xx unknown
-
1994
- 1994-08-24 NL NL940015C patent/NL940015I2/nl unknown
-
1995
- 1995-12-21 HK HK192095A patent/HK192095A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69734742T2 (de) | Arzneizusammensetzungen enthaltend Ascomycinderivate | |
| DE2601207C3 (de) | Verfahren zur Herstellung einer flüssigen pharmazeutischen Zubereitung mit gesteuertem Arzneimittelabgabevermögen | |
| DE69839224T2 (de) | Pharmazeutische zusammensetzung enthaltend cyclodextrine und taxoide | |
| DE60116084T2 (de) | Parenteral anzuwendende stabilisierte wässrige suspensionen | |
| DE69936911T2 (de) | Propofolhaltiges arzneimittel enthaltend sulfite | |
| DE602004000982T2 (de) | Intranasale formulierung mit rotigotin | |
| DE60105322T2 (de) | Wässerige zusammensetzung enthaltend amphotericin b | |
| DE69920201T2 (de) | Zusammensetzungen enthaltend glykolderivate, alkohole und vitamin d | |
| EP0733372A2 (de) | Pharmazeutische Formulierungsgrundlage für Nanosuspensionen | |
| CH693764A5 (de) | Pharmazeutische Zusammensetzung enthaltend Propofol und Edetat. | |
| DE3008082A1 (de) | Carcinostatisches und die immunreaktion stimulierendes mittel, enthaltend lysophospholipid und phospholipid, und verfahren zur herstellung desselben | |
| EP0711556A1 (de) | Intravenöse Lösungen für ein Staurosporinderivat | |
| DE1792410B2 (de) | Arzneimittelzubereitung zur intravenösen Injektion | |
| EP1750700A1 (de) | Flüssige zubereitung für die veterinärmedizin; verfahren zu deren herstellung und deren verwendung | |
| EP0181287B1 (de) | Trockensubstanzen und stabile Suspensionen | |
| EP0675709B1 (de) | Lyopilisierte, wirkstoffhaltige emulsion | |
| EP0705601A1 (de) | Lösungen von Anthrachinonen zur parenteralen Applikation | |
| EP0336000B1 (de) | Ambiphile Creme | |
| DE4038385A1 (de) | Sitosterol und seine glykoside mit verbesserter bioverfuegbarkeit | |
| EP0866689A1 (de) | Cortisolspray zur topischen verabreichung | |
| DE1620629C3 (de) | Verwendung eines Salzes von 2-Merkaptoäthansulf onsäure zur Herstellung von Mukolytica | |
| EP0470437B1 (de) | Wässriges Liposomensystem | |
| DE60120630T2 (de) | Pharmazeutische Zusammensetzung enthaltend Xanthangummi | |
| DE69922252T2 (de) | Parenterale lösungen enthaltend propofol (2,6-diisopropylphenol) und 2.5-di-0-methyl-1.4;3.6-dianhydro-d-glucitol als lösungsmittel | |
| DE60127140T2 (de) | Amphotericin b enthaltende strukturierte emulsion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |